Castration-Resistant Prostate Cancer Therapeutics Market Report

Europe Castration-Resistant Prostate Cancer Therapeutics Market Size, Status and Forecast 2014-2026

  • POSTDATE：Oct 18, 2019
  • PAGES：146
  • REPORT CODE：GMM328771
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Castration-Resistant Prostate Cancer Therapeutics market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 14.2% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Castration-Resistant Prostate Cancer Therapeutics Market Segmentations:

    By Player:

    • Johnson & Johnson

    • Sanofi

    • Bayer

    • Dendreon Corporation

    • Astellas Pharma Inc

    By Type:

    • Type 1

    • Type 2

    • Type 3

    By End-User:

    • End-Users 1

    • End-Users 2

    • End-Users 3

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Castration-Resistant Prostate Cancer Therapeutics Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 1 from 2014 to 2026

    • 1.3.2 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 2 from 2014 to 2026

    • 1.3.3 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 3 from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 1 from 2014 to 2026

    • 1.4.2 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 2 from 2014 to 2026

    • 1.4.3 Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Castration-Resistant Prostate Cancer Therapeutics Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Castration-Resistant Prostate Cancer Therapeutics by Major Types

      • 3.4.1 Market Size and Growth Rate of Type 1

      • 3.4.2 Market Size and Growth Rate of Type 2

      • 3.4.3 Market Size and Growth Rate of Type 3

    4 Segmentation of Castration-Resistant Prostate Cancer Therapeutics Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Castration-Resistant Prostate Cancer Therapeutics by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Castration-Resistant Prostate Cancer Therapeutics for End-Users 1

      • 4.4.2 Market Size and Growth Rate of Castration-Resistant Prostate Cancer Therapeutics for End-Users 2

      • 4.4.3 Market Size and Growth Rate of Castration-Resistant Prostate Cancer Therapeutics for End-Users 3

    5 Market Analysis by Major Regions

    • 5.1 Europe Castration-Resistant Prostate Cancer Therapeutics Production Analysis by Top Regions

    • 5.2 Europe Castration-Resistant Prostate Cancer Therapeutics Consumption Analysis by Top Regions

    • 5.3 Europe Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.3 France Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    6 Product Circulation of Castration-Resistant Prostate Cancer Therapeutics Market among Top Countries

    • 6.1 Top 5 Export Countries in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 7.1 Germany Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 7.2 Germany Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    8. UK Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 8.1 UK Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 8.2 UK Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    9. France Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 9.1 France Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 9.2 France Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    10. Italy Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 10.1 Italy Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 10.2 Italy Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    11. Spain Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 11.1 Spain Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 11.2 Spain Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    12. Poland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 12.1 Poland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 12.2 Poland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    13. Russia Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 13.1 Russia Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 13.2 Russia Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    14. Switzerland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 14.1 Switzerland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 14.2 Switzerland Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    15. Turkey Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 15.1 Turkey Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 15.2 Turkey Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Top Countries

      • 16.3.1 Denmark Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 16.3.2 Finland Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 16.3.3 Norway Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 16.3.4 Sweden Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 16.3.6 Iceland Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Top Countries

      • 17.3.1 Belgium Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 17.3.2 Netherlands Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 17.3.3 Luxembourg Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Landscape Analysis by Top Countries

      • 18.3.1 Estonia Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 18.3.2 Latvia Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

      • 18.3.3 Lithuania Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Johnson & Johnson

      • 19.1.1 Johnson & Johnson Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Sanofi

      • 19.2.1 Sanofi Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Bayer

      • 19.3.1 Bayer Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Dendreon Corporation

      • 19.4.1 Dendreon Corporation Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Astellas Pharma Inc

      • 19.5.1 Astellas Pharma Inc Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    The List of Tables and Figures (Totals 65 Figures and 146 Tables)

    • Figure Product Picture

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 1 from 2014 to 2026

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 2 from 2014 to 2026

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of Type 3 from 2014 to 2026

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 1 from 2014 to 2026

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 2 from 2014 to 2026

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • Figure Germany Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure UK Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure France Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Castration-Resistant Prostate Cancer Therapeutics Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Castration-Resistant Prostate Cancer Therapeutics Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Castration-Resistant Prostate Cancer Therapeutics

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Castration-Resistant Prostate Cancer Therapeutics by Different Types from 2014 to 2026

    • Table Consumption Share of Castration-Resistant Prostate Cancer Therapeutics by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Type 1

    • Figure Market Size and Growth Rate of Type 2

    • Figure Market Size and Growth Rate of Type 3

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Castration-Resistant Prostate Cancer Therapeutics by Different End-Users from 2014 to 2026

    • Table Consumption Share of Castration-Resistant Prostate Cancer Therapeutics by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of End-User 1

    • Figure Market Size and Growth Rate of End-User 2

    • Figure Market Size and Growth Rate of End-User 3

    • Table Europe Castration-Resistant Prostate Cancer Therapeutics Production by Major Regions

    • Table Europe Castration-Resistant Prostate Cancer Therapeutics Production Share by Major Regions

    • Figure Europe Castration-Resistant Prostate Cancer Therapeutics Production Share by Major Countries and Regions in 2014

    • Table Europe Castration-Resistant Prostate Cancer Therapeutics Consumption by Major Regions

    • Table Europe Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Major Regions

    • Table Germany Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table UK Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table France Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Italy Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Spain Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Poland Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Russia Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Switzerland Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Turkey Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Castration-Resistant Prostate Cancer Therapeutics Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Germany Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Germany Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Germany Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table UK Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table UK Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table UK Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table UK Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table France Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table France Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table France Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table France Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Italy Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Italy Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Italy Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Italy Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Spain Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Spain Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Spain Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Spain Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Poland Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Poland Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Poland Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Poland Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Russia Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Russia Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Russia Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Russia Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Switzerland Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Switzerland Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Switzerland Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Turkey Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Turkey Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Turkey Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Castration-Resistant Prostate Cancer Therapeutics Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Castration-Resistant Prostate Cancer Therapeutics Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

    • Table Company Profile and Development Status of Bayer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

    • Figure Sales and Growth Rate Analysis of Bayer

    • Figure Revenue and Market Share Analysis of Bayer

    • Table Product and Service Introduction of Bayer

    • Table Company Profile and Development Status of Dendreon Corporation

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dendreon Corporation

    • Figure Sales and Growth Rate Analysis of Dendreon Corporation

    • Figure Revenue and Market Share Analysis of Dendreon Corporation

    • Table Product and Service Introduction of Dendreon Corporation

    • Table Company Profile and Development Status of Astellas Pharma Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Astellas Pharma Inc

    • Figure Sales and Growth Rate Analysis of Astellas Pharma Inc

    • Figure Revenue and Market Share Analysis of Astellas Pharma Inc

    • Table Product and Service Introduction of Astellas Pharma Inc

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US